Mandiant Stock Soars by 17% Amid Rumors of Microsoft Acquisition

By Kirsteen Mackay

Published:

Acquisition rumours, an interesting partnership and Q4 earnings beat are giving Mandiant (NASDAQ: MNDT) a moment in the sun.

why-is-mandiant-price-up.

Mandiant (NASDAQ: MNDT) has enjoyed a 17% share price bounce after a Bloomberg report suggested Microsoft (NASDAQ: MSFT) indicated it might be thinking about buying the company.

Meanwhile, Mandiant revealed a new partnership with cyber firm SentinelOne (NYSE: S) to use its Singularity XDR platform as part of Mandiant’s incident response services.

What is Mandiant?

Mandiant is a publicly-traded American cybersecurity firm. It rose to prominence in February 2013 when it released a report directly implicating China in cyber espionage. On 30 December 2013, FireEye acquired Mandiant in a stock and cash deal worth more than $1bn.

In 2021 FireEye sold off Mandiant, and it went solo again. The buyer was the private equity firm Symphony Technology Group.

On 8 February, Mandiant reported its Q4 earnings beating analyst estimates on revenue and earnings. Trading volume for Mandiant was 3x higher that day than the prior 30-day average.

Q4 Highlights

  • EPS: ($0.10)

  • Revenue: $133m

  • Market Cap: $4bn

Q1 Guidance

Guidance comes below analyst expectations for Q1, 2022.

  • EPS: ($0.13) to ($0.15)

  • Revenue: $128m to $131m

FY 2022 Guidance

Guidance comes below analyst expectations for full-year 2022.

  • EPS: ($0.36) to ($0.38)

  • Revenue: $555m to $565m

MNDT Stock: $20 Price Target from Piper Sandler

Rob D. Owens, a senior research analyst at Piper Sandler & Co, reiterated his November price target of $20 on 9 February, maintaining a Hold rating on MNDT stock.

Who are Mandiant competitors?

Mandiant rivals and comparable companies include:

  • Cisco Systems (NASDAQ: CSCO)

  • IBM (NYSE: IBM)

  • Palo Alto Networks (NASDAQ: PANW)

  • Fortinet Inc (NASDAQ: FTNT)

  • CrowdStrike Holdings (NASDAQ: CRWD)

We’ve also produced in-depth reports on ESG investing and Healthcare investing. Or check out our 12 investing themes for 2022.

Explore more on these topics:

Share:

IMPORTANT NOTICE AND DISCLAIMER

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Kirsteen Mackay does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Kirsteen Mackay has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter